Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor
Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin. Appl. Thromb. Hemost. 2009 15 : 9S 16S.
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trial
DOI 10.1016/S0140-6736(07)61445-7, PII S0140673607614457
Eriksson BI, Dahl OE, Rosencher N et al., RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trial. Lancet 2007 370 : 949 956. (Pubitemid 47393577)
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: The RE-MODEL randomized trial
DOI 10.1111/j.1538-7836.2007.02748.x
Eriksson BI, Dahl OE, Rosencher N et al. Oral dabigatran etexilate vs subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: The RE-MODEL randomized trial. J. Thromb. Haemost. 2007 5 : 2178 2185. (Pubitemid 47617868)
Boehringer Ingelheim Limitted. Pradaxa: Summary of product characteristics. Cited 24 March 2010]. Available from URL
Boehringer Ingelheim Limitted. Pradaxa: Summary of product characteristics Cited 24 March 2010]. Available from URL: http://www.pradaxa. com/HCP/Home/prescribing-information/index.jsp
* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.